Baldwin Brothers Inc. MA Trims Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Baldwin Brothers Inc. MA lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,252 shares of the company’s stock after selling 271 shares during the period. Baldwin Brothers Inc. MA’s holdings in IDEXX Laboratories were worth $5,996,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. IFM Investors Pty Ltd boosted its holdings in IDEXX Laboratories by 9.2% in the third quarter. IFM Investors Pty Ltd now owns 7,005 shares of the company’s stock valued at $2,754,000 after purchasing an additional 588 shares during the last quarter. Vigilant Capital Management LLC lifted its holdings in IDEXX Laboratories by 19.5% during the 3rd quarter. Vigilant Capital Management LLC now owns 1,224 shares of the company’s stock worth $481,000 after buying an additional 200 shares during the last quarter. Diversified Trust Co lifted its holdings in IDEXX Laboratories by 58.1% during the 3rd quarter. Diversified Trust Co now owns 1,010 shares of the company’s stock worth $397,000 after buying an additional 371 shares during the last quarter. Avantax Advisory Services Inc. bought a new position in IDEXX Laboratories during the 3rd quarter worth approximately $245,000. Finally, MinichMacGregor Wealth Management LLC lifted its holdings in IDEXX Laboratories by 5.5% during the 3rd quarter. MinichMacGregor Wealth Management LLC now owns 1,973 shares of the company’s stock worth $775,000 after buying an additional 102 shares during the last quarter. 87.01% of the stock is owned by hedge funds and other institutional investors.

In related news, VP Giovani Twigge sold 7,316 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $388.19, for a total value of $2,839,998.04. Following the sale, the vice president now directly owns 14,222 shares in the company, valued at approximately $5,520,838.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Nimrata Hunt sold 2,776 shares of IDEXX Laboratories stock in a transaction on Friday, August 14th. The shares were sold at an average price of $377.50, for a total value of $1,047,940.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 122,316 shares of company stock worth $46,594,823. 2.53% of the stock is owned by insiders.

IDXX has been the topic of a number of research analyst reports. BidaskClub raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, October 1st. Bank of America increased their target price on IDEXX Laboratories from $300.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Stifel Nicolaus increased their target price on IDEXX Laboratories from $280.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Credit Suisse Group increased their price target on IDEXX Laboratories from $415.00 to $422.00 and gave the stock an “outperform” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $357.40.

Shares of IDEXX Laboratories stock traded up $1.03 on Friday, reaching $423.75. 269,540 shares of the company were exchanged, compared to its average volume of 554,780. The company has a debt-to-equity ratio of 3.29, a quick ratio of 1.02 and a current ratio of 1.44. The company’s 50-day moving average is $381.27 and its two-hundred day moving average is $332.95. The firm has a market cap of $36.04 billion, a price-to-earnings ratio of 80.10, a P/E/G ratio of 4.79 and a beta of 0.81. IDEXX Laboratories, Inc. has a 1-year low of $168.65 and a 1-year high of $430.86.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Friday, July 31st. The company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.17 by $0.55. IDEXX Laboratories had a return on equity of 241.52% and a net margin of 18.59%. The firm had revenue of $637.20 million for the quarter, compared to analysts’ expectations of $589.98 million. During the same period last year, the firm earned $1.43 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 5.72 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: Market Indexes

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply